REGN
Regeneron Pharmaceuticals, Inc.
September 28, 2026 · intraday
- Rarity
- 1.44
- Peak move
- −4.75%
- Float cap
- $80.1B
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates target eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. It provides these medicines to patients and medical professionals.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
1 event · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingRBC Capital maintained a Hold (Sector Perform) rating on Regeneron Pharmaceuticals with a $737 price target on Sep 24, 2026, implying about 6.5% downside to the prior close.